SAN DIEGO--(BUSINESS WIRE)--

Illumina, Inc. (ILMN) today announced five initial TruSight content sets for use in next-generation sequencing (NGS) in laboratory settings. Designed by recognized experts at leading institutions, the content sets offer cost-effective, streamlined, targeted sequencing for specific genetic diseases or conditions. Customers can immediately leverage this content to develop their own tests, and in the first half of 2013 will have the additional capability to augment the sets with custom content.

These products, developed in conjunction with leading healthcare experts including Childrens Mercy Center for Pediatric Genomic Medicine, Kennedy Krieger Institute, The Institute of Cancer Research, London, and Partners HealthCare (see additional Illumina-Partners HealthCare news today), are designed to provide comprehensive evaluation of genes associated with the following:

The launch of these new NGS products is an exciting milestone for Illumina, said Jay Flatley, President and Chief Executive Officer for Illumina. We worked closely with the community to develop and introduce these first content sets, to ensure we are meeting the needs of laboratories and to enable results of high quality. Combining this content with already proven Illumina next-generation sequencing technology, via the MiSeq platform, will provide a powerful tool.

TruSight content sets are comprised of oligo probes that target specific genes and regions relevant to specific diseases or conditions. They are designed for use by laboratories in the development of their own unique targeted sequencing tests and will work on Illuminas MiSeq system. Additionally, new Nextera Enrichment kits and MiSeq kits will support lower sample throughput options.

We are very excited about the value of the new content and how accessible it will be to laboratories, said Dr. Stephen Kingsmore, Director, Childrens Mercy Center for Pediatric Genomic Medicine, in Kansas City, Mo. Deploying this expert content on Illuminas proven technology streamlines a labs operational efficiency and speed to results. Ultimately, we hope to improve patient care. Thats the true goal.

Added Matt Posard, Senior Vice President and General Manager of Illuminas Translational and Consumer Genomics business, Today, Illumina also announced a strategic alliance with Partners HealthCare to introduce next-generation sequencing clinical interpretation and reporting tools, via their GeneInsight Suite platform. The combination of TruSight products and these new interpretation and reporting tools is a major step forward in realizing the benefits of next generation sequencing.

TruSight content sets are for research use only and not intended for diagnostic use. The products are now available for order with shipment to begin in Q4 2012. For more information, visit http://www.illumina.com/TruSight.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Go here to see the original:
Illumina Launches TruSightTM Targeted Sequencing Content Sets

Comments are closed.